When do the federal regulations allow placebo-controlled trials in children?

Journal of Pediatrics

Volumn 142, Issue 2, 2003, Pages 102-107

  Miller, Franklin G ^a   Wendler, David ^a   Wilfond, Benjamin ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLERGIC RHINITIS; CHILD; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEADACHE; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; NOTE; PEDIATRICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0037328996     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2003.43     Document Type: Note

References (27)

1. NIH policy and guidelines on the inclusion of children as participants in research involving human subjects. March 6, 1998. Available at: http://www.nih.gov/grants/guide/notice-files/not98-024.html.
2. Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. FR Doc. 98-31901:66631-66672.
3. Food and Drug Administration Modernization Act of 1997, Section 505A. Available at: http://www.fda.gov/opacom/7modact.html.
4. Department of Health and Human Services. Protection of human subjects. Code of Federal Regulations. 45CFR46, 1991.
5. Department of Health and Human Services. Protection of Human Subjects. Code of Federal Regulations 45CFR46 Subpart D - Additional DHHS protections for children involved as subjects in research, 1991.
6. Food and Drug Administration. Additional safeguards for children in clinical investigations of FDA-regulated products. Federal Register April 24, 2001;66:20589-20600.
7. Freedman B, Glass KC, Weijer C. Placebo orthodoxy in clinical research, II. Ethical, legal and regulatory myths. J Law Med Ethics 1996;24:252-9.
8. Temple R, Ellenberg SE. Placebo-controlled trials and active-control trials in the evaluation of new treatments: part 1: ethical and scientific issues. Ann Intern Med 2000;133:455-63.
9. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials - a middle ground. N Engl J Med 2001;345:915-9.
10. Weijer C. The ethical analysis of risk. J Law Med Ethics 2000;28:344-61.
11. National Bioethics Advisory Commission. Ethical and policy issues in research involving human participants. Vol. 1, Report and recommendations of the National Bioethics Advisory Commission. Bethesda (MD): National Bioethics Advisory Commission; 2001. p. 77.
12. Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med 1999;341:531-4.
13. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research involving children. Washington (DC): Department of Health, Education, and Welfare; 1977. p. 7.
14. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-8.
15. Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized,double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16.
16. ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, et al. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000;118:303-12.
17. Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001;86:203-10.
18. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7.
19. American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995;95:286-94.
20. Hrobjartsson A, Gotzche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.
21. Spiegel D, Karemer H, Carlson RW. Is the placebo powerless? N Engl J Med 2001;345:1276.
22. Miller FG. Is the placebo powerless? N Engl J Med 2001;345:1277.
23. Kaptchuk TJ. Is the placebo powerless? N Engl J Med 2001;345:1277.
24. de la Fuente-Fernandez R, Ruth TJ, Sossi V, et al. Mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-6.
25. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531-8.
26. Wagner KD, Ambrosnin PJ. Childhood depression: pharmacological therapy/treatment. J Clin Child Psychol 2001;30:88-97.
27. Ambrosini PJ. A review of pharmacotherapy of major depression in children and adolescents. Psychiatr Serv 2000;51:627-33.